Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
The Data Monitoring Committee (DMC) of the BHF-PROTECT-TAVI trial determined “there is little prospect of demonstrating a benefit in the primary endpoint.” Moreover, given the confidence intervals, ...